AION Labs Has Launched An Artificial Intelligence Company To Enhance Drug Trials
AION Labs has developed OMEC.AI, the lab’s first Israeli Innovation Authority-approved startup. The new firm will provide (Artificial Intelligence) AI-powered solutions to assess preclinical data and detect loopholes in efficacy and safety to increase the likelihood of drug candidates’ success in clinical trials.
OMEC.AI seeks to develop a next-generation computational platform capable of identifying latent safety risks and lack of efficacy in drug candidates and recommending trials to fix the identified gaps. AION Labs and its pharmaceutical partners will give OMEC.AI pharmaceutical data for model training and advanced machine learning research, in addition to money, assistance, and mentorship.
OMEC.AI Ori Shachar and Amir Harel will lead AI, both veterans of Mobileye, an Israeli technology company that developed autonomous driving technologies and was purchased by Intel in 2017 for $15.3 billion.
“Currently, there is no automated system that utilises all preclinical data to provide a valid assessment of a drug candidate’s clinical trial preparedness.” “We want to bridge that gap,” said Shachar, co-founder and CEO of OMEC.AI.
“We intend to create a cutting-edge technology with the support of AION Labs and its partners to considerably improve the probability of success of drug candidates that make it to the clinical trial phase.”
Most drug candidates fail in clinical trials due to unanticipated safety concerns or a lack of efficacy in human beings. Omics technology has advanced substantially recently, allowing for long-term tissue and single-cell profiling. These technologies are used broadly in preclinical in-vitro and in-vivo studies. These multi-omics datasets, however, are heterogeneous and inaccurate in forecasting human biology, according to the business.
Also Read,
OMEC.AI strives to provide an automated system that uses all preclinical data to provide a trustworthy assessment of a drug candidate’s clinical trial readiness.
OMEC.AI is AION Labs’ first firm that produces early-stage startup teams that use Artificial Intelligence to change the drug process of research and development to benefit human health.
The new company was founded with investments from Pfizer, AstraZeneca, and Merck, close collaboration from Amazon Web Services (AWS) and extra funding from the Israel Innovation Authority.
“The establishment of OMEC.AI is an important step in our mission to improve drug discovery and patient care via innovation,” stated Mati Gill, CEO of AION Labs.
“We are thrilled to welcome OMEC.AI to the AION Labs family and to collaborate with them to transform drug development.”
Also Read,
